|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NCCRP1 |
Gene summary for NCCRP1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NCCRP1 | Gene ID | 342897 |
| Gene name | NCCRP1, F-box associated domain containing | |
| Gene Alias | FBXO50 | |
| Cytomap | 19q13.2 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q6ZVX7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 342897 | NCCRP1 | sample3 | Human | Cervix | CC | 5.76e-04 | 1.72e-01 | 0.1387 |
| 342897 | NCCRP1 | H2 | Human | Cervix | HSIL_HPV | 1.65e-16 | 5.28e-01 | 0.0632 |
| 342897 | NCCRP1 | T3 | Human | Cervix | CC | 1.13e-04 | 2.00e-01 | 0.1389 |
| 342897 | NCCRP1 | P1T-E | Human | Esophagus | ESCC | 1.73e-03 | 7.56e-01 | 0.0875 |
| 342897 | NCCRP1 | P17T-E | Human | Esophagus | ESCC | 1.39e-04 | 3.39e-01 | 0.1278 |
| 342897 | NCCRP1 | P24T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.98e-01 | 0.1287 |
| 342897 | NCCRP1 | P31T-E | Human | Esophagus | ESCC | 7.90e-03 | 7.20e-01 | 0.1251 |
| 342897 | NCCRP1 | P39T-E | Human | Esophagus | ESCC | 1.53e-11 | 8.25e-01 | 0.0894 |
| 342897 | NCCRP1 | P47T-E | Human | Esophagus | ESCC | 3.97e-04 | 4.21e-01 | 0.1067 |
| 342897 | NCCRP1 | P57T-E | Human | Esophagus | ESCC | 7.90e-03 | 1.74e-01 | 0.0926 |
| 342897 | NCCRP1 | P74T-E | Human | Esophagus | ESCC | 5.81e-17 | 1.10e+00 | 0.1479 |
| 342897 | NCCRP1 | P75T-E | Human | Esophagus | ESCC | 2.78e-39 | 1.32e+00 | 0.1125 |
| 342897 | NCCRP1 | P76T-E | Human | Esophagus | ESCC | 4.41e-07 | 2.25e-01 | 0.1207 |
| 342897 | NCCRP1 | P79T-E | Human | Esophagus | ESCC | 3.02e-26 | 6.02e-01 | 0.1154 |
| 342897 | NCCRP1 | P82T-E | Human | Esophagus | ESCC | 8.68e-07 | 1.59e+00 | 0.1072 |
| 342897 | NCCRP1 | P84T-E | Human | Esophagus | ESCC | 8.80e-03 | 1.65e+00 | 0.0933 |
| 342897 | NCCRP1 | C21 | Human | Oral cavity | OSCC | 2.51e-02 | 1.64e+00 | 0.2678 |
| 342897 | NCCRP1 | C46 | Human | Oral cavity | OSCC | 2.78e-05 | 3.82e-01 | 0.1673 |
| 342897 | NCCRP1 | C57 | Human | Oral cavity | OSCC | 3.73e-02 | 6.03e-01 | 0.1679 |
| 342897 | NCCRP1 | LN46 | Human | Oral cavity | OSCC | 2.54e-02 | 6.01e-01 | 0.1666 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001049810 | Cervix | CC | proteasomal protein catabolic process | 111/2311 | 490/18723 | 8.98e-11 | 1.58e-08 | 111 |
| GO:004316110 | Cervix | CC | proteasome-mediated ubiquitin-dependent protein catabolic process | 91/2311 | 412/18723 | 1.65e-08 | 1.25e-06 | 91 |
| GO:003497610 | Cervix | CC | response to endoplasmic reticulum stress | 57/2311 | 256/18723 | 5.81e-06 | 1.42e-04 | 57 |
| GO:003497615 | Cervix | HSIL_HPV | response to endoplasmic reticulum stress | 20/737 | 256/18723 | 2.88e-03 | 2.70e-02 | 20 |
| GO:0010498111 | Esophagus | ESCC | proteasomal protein catabolic process | 369/8552 | 490/18723 | 1.13e-41 | 1.80e-38 | 369 |
| GO:0043161111 | Esophagus | ESCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 312/8552 | 412/18723 | 3.53e-36 | 4.48e-33 | 312 |
| GO:0034976111 | Esophagus | ESCC | response to endoplasmic reticulum stress | 192/8552 | 256/18723 | 7.15e-22 | 1.30e-19 | 192 |
| GO:003650315 | Esophagus | ESCC | ERAD pathway | 82/8552 | 107/18723 | 5.80e-11 | 1.84e-09 | 82 |
| GO:003043314 | Esophagus | ESCC | ubiquitin-dependent ERAD pathway | 66/8552 | 85/18723 | 1.64e-09 | 3.78e-08 | 66 |
| GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
| GO:19011362 | Esophagus | ESCC | carbohydrate derivative catabolic process | 99/8552 | 172/18723 | 1.11e-03 | 5.54e-03 | 99 |
| GO:00311461 | Esophagus | ESCC | SCF-dependent proteasomal ubiquitin-dependent protein catabolic process | 33/8552 | 49/18723 | 1.80e-03 | 8.26e-03 | 33 |
| GO:0006516 | Esophagus | ESCC | glycoprotein catabolic process | 19/8552 | 28/18723 | 1.49e-02 | 4.84e-02 | 19 |
| GO:001049820 | Oral cavity | OSCC | proteasomal protein catabolic process | 336/7305 | 490/18723 | 5.45e-41 | 8.63e-38 | 336 |
| GO:004316120 | Oral cavity | OSCC | proteasome-mediated ubiquitin-dependent protein catabolic process | 285/7305 | 412/18723 | 5.68e-36 | 5.99e-33 | 285 |
| GO:003497620 | Oral cavity | OSCC | response to endoplasmic reticulum stress | 178/7305 | 256/18723 | 2.59e-23 | 6.06e-21 | 178 |
| GO:00304334 | Oral cavity | OSCC | ubiquitin-dependent ERAD pathway | 65/7305 | 85/18723 | 2.12e-12 | 8.99e-11 | 65 |
| GO:00365035 | Oral cavity | OSCC | ERAD pathway | 76/7305 | 107/18723 | 1.76e-11 | 6.11e-10 | 76 |
| GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
| GO:19011361 | Oral cavity | OSCC | carbohydrate derivative catabolic process | 89/7305 | 172/18723 | 4.52e-04 | 2.73e-03 | 89 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NCCRP1 | SNV | Missense_Mutation | rs751942514 | c.418N>G | p.Tyr140Asp | p.Y140D | Q6ZVX7 | protein_coding | tolerated(0.63) | benign(0.022) | TCGA-D8-A1XG-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| NCCRP1 | SNV | Missense_Mutation | rs751942514 | c.418T>G | p.Tyr140Asp | p.Y140D | Q6ZVX7 | protein_coding | tolerated(0.63) | benign(0.022) | TCGA-EW-A1PH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| NCCRP1 | deletion | Frame_Shift_Del | novel | c.599delN | p.Leu200ArgfsTer65 | p.L200Rfs*65 | Q6ZVX7 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| NCCRP1 | SNV | Missense_Mutation | rs759181864 | c.605N>T | p.Ala202Val | p.A202V | Q6ZVX7 | protein_coding | deleterious(0) | benign(0.377) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NCCRP1 | SNV | Missense_Mutation | c.674N>A | p.Gly225Asp | p.G225D | Q6ZVX7 | protein_coding | deleterious(0.03) | probably_damaging(0.985) | TCGA-D5-6540-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| NCCRP1 | SNV | Missense_Mutation | rs763326657 | c.787N>T | p.Arg263Trp | p.R263W | Q6ZVX7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| NCCRP1 | SNV | Missense_Mutation | rs768983205 | c.650G>A | p.Arg217Gln | p.R217Q | Q6ZVX7 | protein_coding | tolerated(0.34) | benign(0.222) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| NCCRP1 | SNV | Missense_Mutation | c.738N>A | p.Phe246Leu | p.F246L | Q6ZVX7 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD | |
| NCCRP1 | SNV | Missense_Mutation | novel | c.713N>A | p.Gly238Asp | p.G238D | Q6ZVX7 | protein_coding | deleterious(0) | possibly_damaging(0.606) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| NCCRP1 | SNV | Missense_Mutation | rs768983205 | c.650N>A | p.Arg217Gln | p.R217Q | Q6ZVX7 | protein_coding | tolerated(0.34) | benign(0.222) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |